Loxo Oncology (LOXO) Tops Q1 EPS by 60c, Beats on Revenues

Loxo Oncology (NASDAQ: LOXO) reported Q1 EPS of ($0.12), $0.60 better than the analyst estimate of ($0.72). Revenue for the quarter came in at $38.43 million versus the consensus estimate of $16.46 million.

For earnings history and earnings-related data on Loxo Oncology (LOXO) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Birchtech Corp. (BCHT) Misses Q2 EPS by 7c
• LogicBio Therapeutics (LOGC) Misses Q2 EPS by 10c